Synapse - Hematologic Malignancies, Division of

Results (13379)

NX-2127-001, first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies

Meeting Abstract

Mato, A. R.; Wierda, W. G.; Ai, W. Z.; Flinn, I. W.; Tees, M.; Patel, M. R.; Patel, K.; O'Brien, S.; Bond, D. A.; Roeker, L. E.; more...
Blood (2022)

Fulltext@MSK | Save

Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with newly diagnosed and relapsed acute leukemia

Meeting Abstract

Nath, K.; Lee, J.; Elko, T. A.; Levy, L.; Preston, E.; Devlin, S. M.; Ponce, D. M.; Lin, R. J.; Shaffer, B. C.; Cho, C.; more...
Blood (2022)

Fulltext@MSK | Save

Hospital costs and healthcare resource utilization (HRU) for chimeric antigen (CAR) T-cell therapy and stem cell transplant (SCT) in patients with large B-cell lymphoma (LBCL) in the United States (US)

Meeting Abstract

Cui, C.; Feng, C.; Rosenthal, N.; Wade, S. W.; Curry, L.; Fu, C.; Shah, G. L.
Blood (2022)

Fulltext@MSK | Save

Systematic evaluation of AML-associated antigens identifies novel anti-U5 snRNP200 therapeutic antibodies for the treatment of AML

Meeting Abstract

Knorr, K.; Erickson, C.; Wang, E.; Rahman, J.; Mi, X.; Lu, S.; Fox, N.; Penson, A.; Hogg, S.; Stanley, R.; more...
Blood (2022)

Fulltext@MSK | Save

Single cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia

Meeting Abstract

Robinson, T.; Bowman, R. L.; Persaud, S.; Liu, Y.; Gao, Q.; Zhang, J. P.; Sun, X.; Sciambi, A.; Llanso, A.; Famulare, C.; more...
Blood (2022)

Fulltext@MSK | Save

MGTA-117, an anti-CD117 antibody-drug conjugated with amanitin, in participants with relapsed/refractory adult acute myeloid leukemia (AML) and myelodysplasia with excess blasts (MDS-EB): Safety, pharmacokinetics and pharmacodynamics initial findings from a phase 1/2 study

Meeting Abstract

Westervelt, P.; Kebriaei, P.; Juckett, M.; Artz, A. S.; Chan, O.; McCarthy, P. L.; Farag, S. S.; Singh, A. K.; Stein, E.; Humphrey, J.; more...
Blood (2022)

Fulltext@MSK | Save

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Meeting Abstract

Ziccheddu, B.; Diamond, B.; Maclachlan, K. H.; Taylor, J.; Boyle, E. M.; Arango Ossa, J. E.; Jacob, J.; Affer, M.; Totiger, T. M.; Coffey, D.; more...
Blood (2022)

Fulltext@MSK | Save

A risk-adapted study to assess the efficacy of enasidenib and subsequent response-driven addition of azacitidine for newly diagnosed IDH2-mutant AML patients: 3-year follow-up

Meeting Abstract

Stein, E.; Cai, S. F.; Huang, Y.; Dunbar, A.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W. G.; Schiller, G. J.; Olin, R. L.; more...
Blood (2022)

Fulltext@MSK | Save

Multicenter phase I study of post-transplant low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

Meeting Abstract

Metheny, L.; Sobecks, R. M.; Cho, C.; Wang, J.; Ciarrone, L.; Caimi, P. F.; Otegbeye, F.; Cooper, B. W.; Gallogly, M.; Malek, E.; more...
Blood (2022)

Fulltext@MSK | Save

Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders

Meeting Abstract

Montoya, S.; Bourcier, J.; Thompson, M. C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Risso, C. B.; Tsai, D.; more...
Blood (2022)

Fulltext@MSK | Save